CellCept-Myofortic

Share This:

Ready to Help Whenever You Need Us

We know who to talk to, where to find answers, and what steps you need to take. Let us put our 30 years of experience to work for you.

CellCept and Myofortic Linked to Pregnancy Loss and Birth Defects

The FDA has issued a warning to healthcare providers and patients that use of the drugs CellCept (mycophenolate mofetil) and Myofortic (mycophenolic acid) during pregnancy is associated with an increased risk of first trimester pregnancy loss and congenital malformations, particularly external ear and facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidney.

Based on post-marketing data from the United States National Transplantation Pregnancy Registry, which showed 15 miscarriages and 4 birth defects among 33 pregnancies with exposure to MMF, the pregnancy category for CellCept and Myfortic has been changed to Category D (positive evidence of fetal risk) and a “black box” warning of the risk of pregnancy loss and congenital malformations was added to the labels of both drugs last year.

FDA Ongoing Investigation into Possible Link to PML

The FDA is also investigating a potential association between the use of CellCept and Myfortic, and the development of progressive multifocal leukoencephalopathy (PML), a rare, life-threatening disorder affecting the central nervous system, usually occurring in patients with suppressed immune systems. Many patients who develop PML do not survive. Those who do may have permanent disability due to irreversible nerve damage.

Signs and symptoms of PML can include vision changes, loss of coordination, clumsiness, memory loss, difficulty speaking or understanding what others say, and weakness in the legs.

If you or your loved one has suffered a CellCept or Myofortic injury, contact us today. Submit the form to the right and we’ll let you know if you have a case and if we can represent you.